Anthony Reder, MD

Professor
Director, Clinical Trials
Director of Infusion Therapy,
Chicago-Greater Illinois Chapter of the NMSS -- Clinical Advisory Committee

Assistant: TBD
Telephone: 773-702-6204
Patient Calls: 773-702-6222
Fax: 773-702-9073
Email: Assistant:
   

Dr. Anthony Reder is an expert on multiple sclerosis (MS) and an instrumental faculty member in the University of Chicago Medicine's large MS program.

Dr. Reder and several other colleagues and residents have developed new treatments for MS. The group has shown that misoprostol (Cytotek) abolishes trigeminal neuralgia in MS. The MS group has also helped develop and test most of the current therapies for MS, including Interferon-beta (Betaseron, Avonex, Rebif, Extavia), glatiramer (Copaxone), natalizumab (Tysabri), and fingolimod (Gilenya). The first FDA-approved therapy, IFN-beta (Betaseron), reduced exacerbations of MS and improved memory, and reduced deaths 20 years later by nearly 50 percent. Several other trials of new MS therapies are currently in progress.

Dr. Reder directs the Neurology and Inflammatory Disease Infusion Center. Here, FDA-approved as well as cutting-edge therapies are used to treat multiple sclerosis, lupus, rheumatoid arthritis, sarcoidosis, and Crohn’s disease.

Dr. Reder has authored a number of papers, abstracts, and presentations at national neurology meetings. Subjects have included multiple sclerosis, EAE, tetanus, neuropsychiatry, sleep, and fatal familial insomnia. His primary research interest is in the interaction between the central nervous system (CNS) and the immune system. He and his colleagues are studying the mechanism of action for interferon--the most widely used treatment for MS. Dr. Reder recently found that there is a defect in the interferon signaling pathway in lymphocytes during attacks and in progressive forms of MS. This may be why patients with progressive MS do not respond clinically to interferon therapy. He was recently awarded a grant from the National MS Society to study the cause of the signaling problem and ways to correct it.

Education & Training
  • Fellowship: NeuroImmunology, The University of Chicago
  • Residency: University of Minnesota
  • Internship: Hennepin County Medical Center, Minneapolis
  • M.D.: University of Michigan Medical School
Board Certification
  • Neurology, American Board of Psychiatry and Neurology
Clinical Interests
  • Neurology
  • Multiple sclerosis
  • Neuromyelitis optica and MS variants
  • Tetanus
  • Trigeminal neuralgia
Research Interests
  • Multiple sclerosis
    • Interferon signaling in MS - molecular mechanisms and clinical effects
    • Immune regulation in MS
    • Neuro-endocrine regulation in MS
    • Clinical Trials of new in therapies for MS
  • Fellowship training in MS
  • Undergraduate education in laboratory investigation
Teaching
  • Clinical supervision plus one month each of Ward and Consults supervision and teaching of Neurology residents
  • Lectures to residents in Neurosurgery, Anesthesia, ENT, Rheumatology, Ophthalmology, and Medicine
  • Lectures to graduate students in the Committees on Neurobiology and Immunology
  • Awarded NIH K24 for mentoring MS Fellows
Society Memberships
  • American Academy of Neurology
  • American Association for Advancement of Science
  • American Association of Immunology
  • American Neurological Association
  • American Society for Neurological Investigation
  • Association of Medical Laboratory Investigation
  • Association of University of Professors of Neurology
  • Brain Research Institute
  • Chicago Association of Immunologists
  • International Society for Interferon Research
  • International Society for NeuroImmunoModulation
  • Society for Experimental Neuropathology
Publications